Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
28.71
-0.34 (-1.17%)
At close: Apr 2, 2026, 4:00 PM EDT
28.50
-0.21 (-0.73%)
After-hours: Apr 2, 2026, 5:33 PM EDT

Maze Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22
1,4271,994---
Market Cap Growth
168.53%----
Enterprise Value
1,1091,670000
Last Close Price
28.7141.43---
PE Ratio
--13.58---
PB Ratio
3.995.62---
P/TBV Ratio
3.475.02---
P/FCF Ratio
--17.68---
P/OCF Ratio
--17.81---
EV/EBITDA Ratio
--11.89---
EV/EBIT Ratio
--11.69---
EV/FCF Ratio
--14.82---
Debt / Equity Ratio
0.050.05-0.07-0.12-0.10
Debt / EBITDA Ratio
-0.17-0.170.44-0.52-0.30
Debt / FCF Ratio
-0.21-0.210.36-0.57-0.32
Net Debt / Equity Ratio
-0.90-0.900.55-0.050.24
Net Debt / EBITDA Ratio
2.272.27-2.79-0.220.63
Net Debt / FCF Ratio
2.832.83-2.27-0.230.67
Asset Turnover
-01.0700
Quick Ratio
15.1615.169.521.794.81
Current Ratio
15.5015.509.762.095.11
Return on Equity (ROE)
-598.95%-598.95%-15.25%30.60%40.69%
Return on Assets (ROA)
-44.82%-44.82%36.10%-89.00%-74.04%
Return on Invested Capital (ROIC)
-438.76%-438.76%193.52%-307.50%-330.64%
Return on Capital Employed (ROCE)
-48.08%-48.08%41.87%-106.91%-85.95%
Earnings Yield
-9.19%-7.36%---
FCF Yield
-7.90%-5.65%---
Buyback Yield / Dilution
-1474.04%-1474.04%-19.33%-13.88%-
Total Shareholder Return
-1474.04%-1474.04%-19.33%-13.88%-
Updated Mar 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q